{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"30"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"30"}],"units":"Participants"}],"description":"Safety and tolerability of CDX-3379 in combination with cetuximab as determined by incidence and severity of adverse events. Percentage of patients reporting one or more adverse events.","groups":[{"description":"During the treatment phase of the study, eligible patients will receive assigned treatments in 3 week cycles until progression.\n\nCDX-3379 and cetuximab: Dose: 12 mg/kg CDX-3379 once every 3 weeks in combination with 400 mg/m2 cetuximab on the first day followed by weekly doses of 250 mg/m2 cetuximab.","id":"OG000","title":"CDX-3379 and Cetuximab"}],"paramType":"COUNT_OF_PARTICIPANTS","reportingStatus":"POSTED","timeFrame":"Following at least one dose of study treatment through 30 days after last dose of CDX-3379.","title":"Incidence of Adverse Events [Safety and Tolerability]","type":"SECONDARY","unitOfMeasure":"Participants"}